Notice NOT-CA-18-067 from the NIH Guide for Grants and Contracts

Notice NOT-DE-19-018 from the NIH Guide for Grants and Contracts

Notice NOT-HL-18-620 from the NIH Guide for Grants and Contracts

Notice NOT-AG-18-008 from the NIH Guide for Grants and Contracts

Notice NOT-MH-18-031 from the NIH Guide for Grants and Contracts

Notice NOT-DE-18-017 from the NIH Guide for Grants and Contracts

Notice NOT-GM-18-027 from the NIH Guide for Grants and Contracts

Notice NOT-HL-18-619 from the NIH Guide for Grants and Contracts

Notice NOT-AI-18-027 from the NIH Guide for Grants and Contracts

Notice NOT-CA-18-063 from the NIH Guide for Grants and Contracts

Funding Opportunity PAR-18-752 from the NIH Guide for Grants and Contracts. This administrative supplement funding opportunity announcement (FOA) from the National Cancer Institute (NCI) is part of the Cancer Moonshot initiative to accelerate cancer research, and was developed in response to a recommendation from the Blue Ribbon Panel of experts charged with advising the National Cancer Advisory Board on exceptional scientific opportunities that could be accelerated through this initiative. As part of the Cancer Moonshot initiative, the NCI created the Drug Resistance and Sensitivity Network (DRSN), a collaborative network of centers of excellence (supported by U54 cooperative agreement awards) focused on using advanced techniques and models to accelerate understanding of issues of cancer resistance or extreme sensitivity to anticancer agents. The DRSN was also developed to assist in issues of cancer drug resistance in the development of NCI investigational new drug (IND) agents (i.e., those that the NCI is developing in collaboration with pharmaceutical industry partners) in NCI-sponsored early phase clinical trials. This FOA supports supplemental funds to current NCI-funded research projects for new interdisciplinary collaborations between non-U54 investigators and DRSN U54-supported investigators to perform research within the scientific scope(s) of the parent grant and/or cooperative agreement award(s) that will lead to improved pre-clinical evaluations of novel discoveries in cancer drug resistance that could ultimately be tested in NCI-sponsored clinical trials.

Funding Opportunity PA-18-751 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) announces the availability of administrative supplements to support aging research that addresses disparities in health, with emphasis on geriatrics and clinical gerontology studies.

Funding Opportunity PA-18-753 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites Research Project Grant (R01) applications to support the development of novel biomarkers and improved HIV incidence assays and algorithms with increased specificity for distinguishing recent (within the first 12 months) from chronic HIV infections.

Funding Opportunity PA-18-754 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites Exploratory/Developmental Grant (R21) applications to support the development of novel biomarkers and improved HIV incidence assays and algorithms with increased specificity for distinguishing recent (within the first 12 months) from chronic HIV infections.

Funding Opportunity RFA-AI-18-017 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) solicits applications that support research on and early development of next generation biologics with the goal of inducing sustained HIV remission.

Funding Opportunity RFA-FD-18-018 from the NIH Guide for Grants and Contracts. The purpose of this project is to develop and implement a virtual bioequivalence trial simulation platform that can be used to perform population-based statistical analysis in complex and computationally intensive physiologically based pharmacokinetic (PBPK) models developed to describe the absorption, distribution and elimination of active pharmaceutical ingredients formulated in complex and non-complex dosage forms administered via oral or non-oral routes. The developed virtual bioequivalence trial simulation platform will be used to generate predictions on the in vivo drug product performance, to perform bioequivalence assessments between brand name and generic drug products and to inform regulatory decisions relating to generic drug development.

Funding Opportunity PAR-18-755 from the NIH Guide for Grants and Contracts. The primary goal of the NIMH Career Transition Award for Tenure-Track Intramural Investigators (K22) Program (hereafter abbreviated as the NIMH Career Transition K22 Program) is to provide support for career intramural investigators at NIMH who aim to transition from the Division of Intramural Research Programs (DIRP) to an independent research faculty position in the extramural community. Applicants should have a demonstrated record of meritorious research in mental health-related fields

Notice NOT-MH-18-032 from the NIH Guide for Grants and Contracts

Notice NOT-AI-18-028 from the NIH Guide for Grants and Contracts

Notice NOT-CA-18-062 from the NIH Guide for Grants and Contracts